Literature DB >> 1632828

Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases in the rat.

Y L Chen1, I Florentin, A M Batt, L Ferrari, J P Giroud, L Chauvelot-Moachon.   

Abstract

Intravenous treatment of male rats with recombinant human interleukin-6 (rhIL6) at 50, 100 and 200 micrograms/kg (corresponding to 4, 8 and 16 x 10(4) U/animal, respectively) reduced the activities of hepatic microsomal cytochrome P450-dependent monoxygenases to varying degrees. Ethylmorphine-N-demethylase activity fell to 53% of control values, an effect similar to that induced by 2.5 mg/kg Escherichia coli lipopolysaccharide (LPS). Ethoxycoumarin-O-deethylase activity was also sensitive to inhibition, whereas IL6 had little effect on the activities of other P450-dependent enzymes, including ethoxyresorufin-O-deethylase. Pentoxyresorufin dealkylase activity, which is representative of the cytochrome P450 IIB 1/2 subfamily, was unaffected by IL6 whereas LPS reduced it to 33.7% of control values. Another hepatocyte-related parameter, serum concentration of alpha 1-acid glycoprotein (AGP), was increased by up to 3.5-fold over baseline by IL6 and 10-fold by LPS. Recombinant human interleukin-1 beta (rhIL1 beta) (10 micrograms/kg, corresponding to 5 x 10(4) U/rat) and recombinant human tumor necrosis factor alpha (rhTNF) (150 micrograms/kg corresponding to 24 x 10(4) U/rat) were both as potent as LPS (2.5 mg/kg) in increasing serum AGP levels and reducing hepatic microsomal monoxygenase activities. IL6 did not potentiate the effects of rhIL1 beta. Hepatic microsomal glucuronyltransferase activities were little affected by LPS and unaffected by rhIL6. Finally, rhIL6 was more potent after i.p. injection than after i.v. or s.c. injection. These results suggest that the effects of LPS, TNF and IL1 on the mixed-function oxidase system in vivo may be due partly to an induction of IL6 in vivo. The different sensitivities of the enzymes to IL6 but not to IL1 or TNF may be due to the involvement of two distinct mechanisms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1632828     DOI: 10.1016/0006-2952(92)90047-m

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

Review 1.  Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.

Authors:  S C Piscitelli; W G Reiss; W D Figg; W P Petros
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

Review 2.  Regulation of drug-metabolizing enzymes by local and systemic liver injuries.

Authors:  Yan Guo; Bingfang Hu; Yang Xie; Timothy R Billiar; Jason L Sperry; Min Huang; Wen Xie
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-01-28       Impact factor: 4.481

3.  Expression of UDP-glucuronosyltransferase isoform mRNAs during inflammation and infection in mouse liver and kidney.

Authors:  Terrilyn A Richardson; Melanie Sherman; Daniel Kalman; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2005-12-08       Impact factor: 3.922

4.  Role of interleukin 6 and corticosteroids in the regulation of expression of glutathione S-transferases in primary cultures of rat hepatocytes.

Authors:  S H Voss; Y Park; S O Kwon; R Whalen; T D Boyer
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

5.  Mechanism of negative regulation of rat glutathione S-transferase A2 by the cytokine interleukin 6.

Authors:  Susan H Voss; Richard Whalen; Thomas D Boyer
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

Review 6.  Pharmacokinetic alterations after severe head injury. Clinical relevance.

Authors:  B A Boucher; S D Hanes
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

7.  Effect of carrageenan-induced granuloma on hepatic cytochrome P-450 isozymes in rats.

Authors:  J Muntané; V Longo; M T Mitjavila; P G Gervasi; M Ingelman-Sundberg
Journal:  Inflammation       Date:  1995-04       Impact factor: 4.092

8.  Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism.

Authors:  S I Shedlofsky; B C Israel; C J McClain; D B Hill; R A Blouin
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

9.  Effects of Plasmodium berghei infection on cytochromes P-450 2E1 and 3A2.

Authors:  K Uhl; J M Grace; D A Kocisko; B T Jennings; A L Mitchell; T G Brewer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Apr-Jun       Impact factor: 2.569

Review 10.  Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.

Authors:  Lucy Darakjian; Malavika Deodhar; Jacques Turgeon; Veronique Michaud
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.